







































Emmanuel Ifeanyi Obeagu                                                                                                      Asian Journal of Dental and Health Sciences. 2025; 5(1):25-29 

[25]                                                                                                                                                                                                                                              AJDHS.COM 

 

 

Available online at ajdhs.com 

Asian Journal of Dental and Health Sciences 
Open Access to Dental and Medical Research 

Copyright  © 2025 The  Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 
which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the 

original author and source are credited  

 

 

The Mentzer Index in Maternal Anemia: An Early Diagnostic Marker 

Emmanuel Ifeanyi Obeagu *  

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe 

Article Info: 
_____________________________________________ 
Article History: 

Received   08 Nov 2024     
Reviewed  10 Dec 2024 
Accepted   06 Jan 2025 
Published 15 March 2025 

_____________________________________________ 
Cite this article as:  

Obeagu EI, The Mentzer Index in Maternal 
Anemia: An Early Diagnostic Marker, Asian 
Journal of Dental and Health Sciences. 2025; 
5(1):25-29                                                                    

DOI: http://dx.doi.org/10.22270/ajdhs.v5i1.115          

Abstract 
_________________________________________________________________________________________________________________ 

Maternal anemia is a prevalent condition that poses significant health risks to both mothers and 
their infants. Accurate and timely diagnosis is crucial for effective management, particularly in 
differentiating between iron deficiency anemia (IDA) and thalassemia trait (TT), two common 
causes of microcytic anemia during pregnancy. The Mentzer Index (MI), a simple and cost-effective 
diagnostic tool, is used to distinguish between these two conditions by calculating the ratio of mean 
corpuscular volume (MCV) to red blood cell (RBC) count. This review explores the utility of the 
Mentzer Index in maternal anemia diagnosis, highlighting its role in early detection and 
management. The Mentzer Index offers a rapid, straightforward approach to identifying the 
underlying cause of anemia in pregnant women, especially in resource-limited settings. A result of 
MI < 13 suggests thalassemia trait, while MI > 13 is indicative of iron deficiency anemia. Early 
differentiation allows for targeted interventions, such as iron supplementation for IDA, and avoids 
unnecessary iron therapy in TT, thus optimizing patient outcomes. Despite its advantages, the MI has 
limitations, particularly in cases of mixed anemia or when other forms of anemia are present. In such 
instances, further diagnostic tests are necessary for an accurate diagnosis. 

Keywords: Mentzer Index, Maternal Anemia, Iron Deficiency, Thalassemia, Early Diagnosis 

*Address for Correspondence:   

Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe 

 

Introduction 

Maternal anemia is a prevalent and significant health 
concern, particularly during pregnancy, affecting 
millions of women worldwide. It is associated with 
numerous maternal and fetal complications, including 
preterm birth, low birth weight, fatigue, and in severe 
cases, maternal mortality. The condition is most 
commonly caused by iron deficiency anemia (IDA), but 
thalassemia trait (TT), a hereditary blood disorder, is 
also a significant contributor, especially in regions 
where it is endemic. Both IDA and TT can lead to 
microcytic anemia, which can present with similar 
clinical features, making it challenging to differentiate 
between the two based on clinical signs alone. An 
accurate and early diagnosis is critical to ensure 
appropriate management and prevent adverse 
outcomes for both mother and child.1-2 Iron deficiency 
anemia during pregnancy occurs due to increased iron 
requirements for fetal growth and maternal blood 
volume expansion. It can be effectively managed with 
iron supplementation, which is the cornerstone of 
treatment for this condition. On the other hand, 
thalassemia trait, a genetic condition that results in 
abnormal hemoglobin production, does not respond to 
iron supplementation and can lead to unnecessary iron 
overload if treated incorrectly. Misdiagnosing 
thalassemia trait as IDA and administering iron 
unnecessarily can cause harm, including iron toxicity, 

and delay the proper diagnosis and treatment. Thus, 
differentiating between these two types of anemia is 
critical to providing the correct therapeutic approach.3-4 

The Mentzer Index (MI) is a simple, cost-effective, and 
widely used diagnostic tool designed to assist clinicians 
in differentiating between IDA and thalassemia trait. 
The MI is calculated by dividing the mean corpuscular 
volume (MCV) by the red blood cell (RBC) count. An MI 
value of less than 13 is typically indicative of 
thalassemia trait, while a value greater than 13 suggests 
iron deficiency anemia. This straightforward formula 
has made the MI a valuable tool in routine clinical 
practice, particularly in settings where access to 
advanced diagnostic techniques, such as hemoglobin 
electrophoresis, may be limited.5 

The utility of the Mentzer Index lies in its ability to 
provide a rapid and inexpensive preliminary diagnosis 
of microcytic anemia, especially in populations at high 
risk for thalassemia. In many cases, it can offer sufficient 
guidance for initial treatment decisions, enabling 
clinicians to either begin iron supplementation for IDA 
or avoid unnecessary iron therapy for patients with 
thalassemia trait. However, despite its ease of use and 
accessibility, the Mentzer Index is not without 
limitations. It can be less reliable in cases of mixed 
anemia or when the patient has multiple underlying 
causes of anemia. Furthermore, it is not effective in 
diagnosing other types of anemia, such as those caused 

                     Open Access                                                                                                                                                                                                                Review Article                                                                           

http://jddtonline.info/
http://dx.doi.org/10.22270/ajdhs.v5i1.115
https://crossmark.crossref.org/dialog/?doi=10.22270/ajdhs.v5i1.115&amp;domain=pdf
https://orcid.org/0000-0002-4538-0161


Emmanuel Ifeanyi Obeagu                                                                                                      Asian Journal of Dental and Health Sciences. 2025; 5(1):25-29 

[26]                                                                                                                                                                                                                                              AJDHS.COM 

by vitamin deficiencies or chronic disease.6-7 In addition 
to its diagnostic utility, the Mentzer Index has important 
implications for maternal anemia management in 
pregnancy. Timely and accurate diagnosis using the MI 
can significantly reduce the risk of maternal and fetal 
complications associated with misdiagnosis. For 
instance, by differentiating between IDA and 
thalassemia trait, clinicians can avoid unnecessary iron 
therapy, which could lead to iron overload and other 
complications in TT. Moreover, the MI can guide 
clinicians in deciding when to seek further diagnostic 
tests, such as serum ferritin levels, hemoglobin 
electrophoresis, or genetic testing for thalassemia, 
ensuring that the appropriate management plan is 
developed for each patient.8-9 Despite its advantages, 
there are challenges and limitations associated with the 
use of the Mentzer Index in clinical practice. It is most 
effective in cases where the underlying cause of anemia 
is either IDA or thalassemia trait, but its usefulness may 
be compromised in situations involving mixed anemia 
or other complicating factors. Additionally, the MI can 
yield ambiguous results in patients with conditions like 
anemia of chronic disease or lead poisoning, where 
other diagnostic approaches would be required. Given 
these constraints, it is essential to use the MI as part of a 
broader diagnostic framework, complementing it with 
additional tests to ensure a comprehensive and accurate 
diagnosis of anemia in pregnancy.10-11 

Application of the Mentzer Index in Maternal 
Anemia 

Maternal anemia is a common and significant health 
issue during pregnancy, with potential risks to both 
maternal and fetal well-being. The most prevalent types 
of anemia during pregnancy are iron deficiency anemia 
(IDA) and thalassemia trait (TT), both of which can 
present with microcytic anemia. Differentiating 
between these two conditions is crucial, as they require 
different management strategies. The Mentzer Index 
(MI), a simple and cost-effective diagnostic tool, plays an 
important role in this differentiation, especially in 
settings where more advanced testing may not be 
accessible.12-13 In pregnancy, the Mentzer Index is 
particularly useful for distinguishing between IDA and 
TT in women who present with microcytic anemia. IDA 
is typically treated with iron supplementation, whereas 
thalassemia trait does not respond to iron and requires 
a different management approach. By calculating the 
ratio of the mean corpuscular volume (MCV) to red 
blood cell (RBC) count, the MI provides a preliminary 
screening tool. If the MI is greater than 13, the diagnosis 
points to iron deficiency anemia, suggesting that iron 
supplementation should be the first line of treatment. In 
contrast, an MI less than 13 suggests a thalassemia trait, 
which does not require iron therapy but may need 
genetic counseling and monitoring.14-15 

The MI is particularly beneficial in low-resource settings 
where other diagnostic methods, such as serum ferritin 
levels or hemoglobin electrophoresis, may not be 
readily available. It allows clinicians to quickly assess 
whether iron deficiency or thalassemia is the likely 
cause of the anemia, facilitating timely interventions 

and avoiding the unnecessary administration of iron in 
women with thalassemia trait. Additionally, the MI can 
serve as a useful tool in prenatal care programs, helping 
to identify women at risk of anemia early in their 
pregnancy, enabling appropriate treatment and 
reducing the likelihood of complications such as 
preterm birth, low birth weight, or maternal fatigue.16-17 

Despite its practical applications, the Mentzer Index is 
not a definitive diagnostic test. It is best used as an 
initial screening tool, with further diagnostic tests 
recommended for confirmation. For instance, if the MI 
suggests thalassemia trait, confirmatory tests such as 
hemoglobin electrophoresis or genetic testing are 
necessary to establish the diagnosis. Similarly, if the MI 
indicates IDA, additional tests, including serum ferritin 
and total iron binding capacity (TIBC), can help confirm 
iron deficiency. The MI also has limitations in cases of 
mixed anemia, anemia of chronic disease, or when other 
underlying conditions contribute to the microcytic 
anemia. In such cases, a more comprehensive diagnostic 
approach is needed.18-19 

Benefits of the Mentzer Index in Maternal 
Anemia Diagnosis 

The Mentzer Index (MI) offers several key advantages 
when used for the diagnosis of maternal anemia, 
particularly in differentiating between iron deficiency 
anemia (IDA) and thalassemia trait (TT). Its simplicity, 
cost-effectiveness, and ease of use make it an invaluable 
tool, especially in resource-limited settings, where 
access to advanced diagnostic tests may be constrained. 
Here are some of the primary benefits of the Mentzer 
Index in the diagnosis of maternal anemia: 

1. Quick and Easy Calculation 

The Mentzer Index is a straightforward, rapid diagnostic 
tool that can be easily calculated using basic laboratory 
results—mean corpuscular volume (MCV) and red 
blood cell (RBC) count. This makes it an efficient 
screening tool, particularly in settings where more 
complex testing might not be feasible. The formula can 
be calculated without specialized equipment, making it 
accessible for clinicians in both rural and urban 
healthcare settings.20 

2. Differentiation Between IDA and Thalassemia 
Trait 

One of the key benefits of the MI is its ability to 
differentiate between two common causes of microcytic 
anemia in pregnancy: iron deficiency anemia (IDA) and 
thalassemia trait (TT). Since these two conditions 
require different management strategies, identifying the 
underlying cause of anemia early is crucial. An MI 
greater than 13 typically indicates IDA, which can be 
treated with iron supplementation, while an MI less 
than 13 suggests thalassemia trait, which does not 
benefit from iron supplementation but may require 
genetic counseling and follow-up care. This early 
differentiation helps avoid unnecessary iron treatment 
and ensures proper management, reducing the risks of 
complications.21 

 



Emmanuel Ifeanyi Obeagu                                                                                                      Asian Journal of Dental and Health Sciences. 2025; 5(1):25-29 

[27]                                                                                                                                                                                                                                              AJDHS.COM 

3. Cost-Effective and Accessible 

The MI is an affordable diagnostic tool, which makes it 
particularly advantageous in low- and middle-income 
countries or resource-poor settings where advanced 
diagnostic tools like hemoglobin electrophoresis or 
serum ferritin testing may not be readily available. By 
using the MI, clinicians can make a more informed 
decision regarding anemia management without the 
need for expensive or sophisticated equipment, thus 
making anemia management more accessible to a 
broader population of pregnant women.21 

4. Improved Prenatal Care and Early Detection 

Incorporating the Mentzer Index into prenatal care 
helps to identify women at risk of anemia early in 
pregnancy. Early detection allows for timely 
intervention, which can prevent the adverse outcomes 
associated with untreated anemia, such as preterm 
birth, low birth weight, maternal fatigue, or 
developmental complications in the fetus. By using the 
MI, healthcare providers can implement more effective 
anemia screening protocols, leading to better overall 
maternal and fetal health outcomes.22 

5. Reduced Risk of Misdiagnosis and Over-
Treatment 

The MI helps reduce the risk of misdiagnosing anemia 
and, consequently, over-treating pregnant women. For 
instance, iron supplementation is ineffective and 
potentially harmful in cases of thalassemia trait, as 
excess iron can lead to iron overload. By identifying the 
underlying cause of anemia through the MI, clinicians 
can avoid unnecessary iron administration, thus 
preventing the side effects of iron therapy, such as 
gastrointestinal discomfort or iron toxicity, and 
ensuring that patients receive the most appropriate 
treatment.23 

6. Facilitates Targeted Interventions 

The Mentzer Index not only aids in identifying the type 
of anemia but also guides subsequent management 
strategies. In cases of iron deficiency, the MI can prompt 
clinicians to initiate iron supplementation or dietary 
interventions. Conversely, in cases of thalassemia trait, 
the MI helps to avoid unnecessary iron treatment while 
focusing on long-term monitoring and genetic 
counseling. This targeted approach ensures more 
effective and personalized care for pregnant women, 
improving the overall healthcare experience and 
maternal outcomes.24 

Limitations and Challenges 

While the Mentzer Index (MI) offers significant 
benefits in diagnosing maternal anemia, particularly in 
differentiating between iron deficiency anemia (IDA) 
and thalassemia trait (TT), it is not without its 
limitations and challenges. It is essential for healthcare 
providers to be aware of these potential drawbacks to 
ensure the MI is used appropriately and effectively as 
part of a comprehensive diagnostic approach. Below are 
some of the key limitations and challenges associated 
with the MI: 

1. Limited Diagnostic Accuracy in Mixed Anemia 

The MI is primarily designed to differentiate between 
IDA and thalassemia trait, both of which commonly 
present as microcytic anemia. However, in cases where 
a pregnant woman has mixed anemia (e.g., a 
combination of IDA and anemia of chronic disease or 
other underlying conditions), the MI may not be reliable. 
Mixed anemias can present with overlapping clinical 
and laboratory features, leading to an ambiguous MI 
result that cannot definitively point to a single cause. 
This makes it challenging to rely solely on the MI in such 
cases, necessitating further diagnostic testing to 
accurately identify the underlying etiology of the 
anemia.25 

2. Influence of Pregnancy-Induced Physiological 
Changes 

Pregnancy induces a variety of physiological changes 
that can affect the results of the MI. For example, the 
increased plasma volume during pregnancy can lead to 
a dilutional effect, reducing the red blood cell count 
(RBC), which may result in a lower MI value. This 
dilution effect can sometimes complicate the 
interpretation of the MI, as it may not accurately reflect 
the actual RBC concentration or MCV, especially in the 
first and second trimesters when pregnancy-induced 
hemodilution is most pronounced. Therefore, the MI 
should be interpreted with caution, especially in early 
pregnancy, as the physiological changes may impact the 
precision of the result.26 

3. Not a Definitive Diagnostic Tool 

While the MI can help differentiate between IDA and TT, 
it is not a definitive diagnostic tool. The MI should be 
considered as a preliminary screening test rather than a 
conclusive diagnostic method. For instance, while a low 
MI (less than 13) strongly suggests thalassemia trait, 
confirmation of thalassemia requires more specific tests 
such as hemoglobin electrophoresis or genetic testing. 
Similarly, if the MI indicates iron deficiency anemia, 
further tests like serum ferritin, total iron-binding 
capacity (TIBC), or transferrin saturation are necessary 
for confirmation. Relying solely on the MI without 
additional confirmatory tests may lead to misdiagnosis 
and suboptimal management.27 

4. Lack of Consideration for Other Anemia Types 

The MI is most effective in differentiating between two 
causes of microcytic anemia (IDA and TT). However, it 
does not account for other forms of anemia that might 
present with similar symptoms, such as anemia of 
chronic disease or vitamin B12 and folate deficiency 
anemia. These conditions may present with normocytic 
or macrocytic anemia and may not be adequately 
detected through the MI. In such cases, additional 
testing beyond the MI is necessary to identify the 
underlying cause of the anemia and provide the most 
appropriate treatment.25 

5. Potential for Misinterpretation 

While the MI is a valuable screening tool, there is 
potential for misinterpretation, especially if the 



Emmanuel Ifeanyi Obeagu                                                                                                      Asian Journal of Dental and Health Sciences. 2025; 5(1):25-29 

[28]                                                                                                                                                                                                                                              AJDHS.COM 

calculated MI value is close to the threshold of 13. For 
example, women with conditions such as mild anemia of 
chronic disease or those in the early stages of iron 
deficiency might present with MI values that fall into a 
grey area, making it difficult to distinguish between IDA 
and thalassemia. In such cases, healthcare providers 
may need to rely on clinical judgment, patient history, 
and additional laboratory tests to refine the diagnosis 
and avoid unnecessary treatments.26 

6. Genetic Factors and Population Variability 

The accuracy of the MI may vary based on population-
specific genetic factors, particularly in regions where 
thalassemia is more prevalent. Different populations 
may exhibit variations in RBC count and MCV that can 
affect the MI calculation. For example, in populations 
with a high prevalence of thalassemia traits or other 
hemoglobinopathies, the MI might not always be as 
reliable in predicting the correct diagnosis. Genetic 
differences in RBC size and volume could skew the MI 
results, limiting its generalizability across diverse 
populations. In such cases, confirmatory tests like 
hemoglobin electrophoresis or DNA analysis are 
essential to accurately diagnose thalassemia.27 

Conclusion 

The Mentzer Index (MI) is a useful, cost-effective, and 
accessible tool for differentiating between iron 
deficiency anemia (IDA) and thalassemia trait (TT) in 
pregnant women. Its ability to provide a quick and easy 
diagnostic aid, particularly in resource-limited settings, 
makes it an invaluable screening tool for maternal 
anemia. By offering early differentiation between these 
two common causes of microcytic anemia, the MI 
supports timely and appropriate management, helping 
to reduce unnecessary treatments like iron 
supplementation, which could be harmful in cases of 
thalassemia trait. 

Conflict of Interest: Author declares no potential 

conflict of interest with respect to the contents, 

authorship, and/or publication of this article. 

Source of Support: Nil 

Funding: The authors declared that this study has 

received no financial support. 

Informed Consent Statement: Not applicable.  

Data Availability Statement: The data supporting in 

this paper are available in the cited references.  

Ethics approval: Not applicable. 

References 

1. Rahman MM, Abe SK, Rahman MS, Kanda M, Narita S, Bilano V, Ota 
E, Gilmour S, Shibuya K. Maternal anemia and risk of adverse birth 
and health outcomes in low-and middle-income countries: 
systematic review and meta-analysis. The American journal of 
clinical nutrition. 2016; 103(2):495-504. 
https://doi.org/10.3945/ajcn.115.107896 PMid:26739036 

2. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias 
of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 
2016;3(3):10-18. https://doi.org/10.22270/ijmspr.v10i2.95 

3. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, 
Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. 
Iron Status of Pregnant and Post-Partum Women with Malaria 
Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and 
Laboratory Research. 2017;5(4):206. 

4. Petrakos G, Andriopoulos P, Tsironi M. Pregnancy in women with 
thalassemia: challenges and solutions. International journal of 
women's health. 2016:441-451. 
https://doi.org/10.2147/IJWH.S89308 PMid:27660493 
PMCid:PMC5019437 

5. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala 
PU, Agu CC. Assessment of Haematological Changes in Pregnant 
Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021 
Apr;9(4):145-148. 

6. Agreen FC, Obeagu EI. Anaemia among pregnant women: A review 
of African pregnant teenagers. Journal of Public Health and 
Nutrition. 2023;6(1):138. 

7. Arora S, Rana D, Kolte S, Dawson L, Dhawan I. Validation of new 
indices for differentiation between iron deficiency anemia and 
beta thalessemia trait, a study in pregnant females. International 
Journal of Scientific Reports. 2018; 4(2):26. 
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20180394 

8. Obeagu EI, Obeagu GU, Insights into Maternal Health: Mentzer Index 
for Early Anemia Detection, International Journal of Medical 
Sciences and Pharma Research,2024;10(4):44-49 
https://doi.org/10.22270/ijmspr.v10i4.122 

9. Obeagu EI, Influence of Hemoglobin Variants on Vaso-Occlusive 
Phenomena in Sickle Cell Anemia: A Review, International Journal 
of Medical Sciences and Pharma Research, 2024;10(2):54-59 
https://doi.org/10.22270/ijmspr.v10i2.104 

10. Iolascon A, Andolfo I, Russo R, Sanchez M, Busti F, Swinkels D, 
Aguilar Martinez P, Bou‐Fakhredin R, Muckenthaler MU, Unal S, 
Porto G. Recommendations for diagnosis, treatment, and 
prevention of iron deficiency and iron deficiency anemia. 
Hemasphere. 2024; 8(7):e108. 
https://doi.org/10.1002/hem3.108 PMid:39011129 
PMCid:PMC11247274 

11. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. 
Evaluation of protein C, protein S and fibrinogen of pregnant 
women with malaria in Owerri metropolis. Madonna University 
journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 
Apr 19;2(2):1-9. 

12. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to 
Mothers with Severe Malaria, HIV, and Transfusion History: A 
Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 
38-58 

13. Sahli CA, Bibi A, Ouali F, Fredj SH, Dakhlaoui B, Othmani R, Laouini 
N, Jouini L, Ouenniche F, Siala H, Touhami I. Red cell indices: 
differentiation between β-thalassemia trait and iron deficiency 
anemia and application to sickle-cell disease and sickle-cell 
thalassemia. Clinical Chemistry and Laboratory Medicine (CCLM). 
2013; 51(11):2115-24. https://doi.org/10.1515/cclm-2013-0354 
PMid:23800659 

14. Hoffmann JJ, Nabbe KC, van den Broek NM. Effect of age and 
gender on reference intervals of red blood cell distribution width 
(RDW) and mean red cell volume (MCV). Clinical Chemistry and 
Laboratory Medicine (CCLM). 2015; 53(12):2015-9. 
https://doi.org/10.1515/cclm-2015-0155 PMid:26536583 

15. Miftahussurur M, Husada D, Ningtyas WS. Association Association 
Of Shine and Lal Index Β-Thalassemia Trait Screening Results with 
Anaemia and Low Birth Weigh. International Journal of Nursing 
And Midwifery Science (IJNMS). 2023; 7(3):290-296. 
https://doi.org/10.29082/IJNMS/2023/Vol7/Iss3/543 

16. Shahid H, Saleem M, Naseer N, Tabussam S, Aziz A, Ullah S. 
Evaluation of Srivastava index to distinguishing Beta-Thalassemia 
Trait from Iron Deficiency. Pakistan Journal of Medical & Health 
Sciences. 2022;16(05):1225. 
https://doi.org/10.53350/pjmhs221651225 

17. Vehapoglu A, Ozgurhan G, Demir AD, Uzuner S, Nursoy MA, 
Turkmen S, Kacan A. Hematological indices for differential 

https://doi.org/10.3945/ajcn.115.107896
https://doi.org/10.22270/ijmspr.v10i2.95
https://doi.org/10.2147/IJWH.S89308
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20180394
https://doi.org/10.22270/ijmspr.v10i4.122
https://doi.org/10.22270/ijmspr.v10i2.104
https://doi.org/10.1002/hem3.108
https://doi.org/10.1515/cclm-2013-0354
https://doi.org/10.1515/cclm-2015-0155
https://doi.org/10.29082/IJNMS/2023/Vol7/Iss3/543
https://doi.org/10.53350/pjmhs221651225


Emmanuel Ifeanyi Obeagu                                                                                                      Asian Journal of Dental and Health Sciences. 2025; 5(1):25-29 

[29]                                                                                                                                                                                                                                              AJDHS.COM 

diagnosis of Beta thalassemia trait and iron deficiency anemia. 
Anemia. 2014; 2014(1):576738. 
https://doi.org/10.1155/2014/576738 PMid:24818016 
PMCid:PMC4003757 

18. Urrechaga E. Discriminant value of% microcytic/% hypochromic 
ratio in the differential diagnosis of microcytic anemia. Clinical 
chemistry and laboratory medicine. 2008;46(12):1752-1758. 
https://doi.org/10.1515/CCLM.2008.355 PMid:19055451 

19. Obeagu EI, Obeagu GU, Anemia in Pregnancy: Mentzer Index as a 
Predictor for Iron Supplementation Needs, International Journal 
of Medical Sciences and Pharma Research, 2024;10(4):39-43 
https://doi.org/10.22270/ijmspr.v10i4.121 

20. Obeagu EI, Obeagu GU. Sickle cell anaemia in pregnancy: a review. 
International Research in Medical and Health Sciences. 2023 Jun 
10;6(2):10-13. https://doi.org/10.22270/ijmspr.v10i2.103 

21. Obeagu EI, Ubosi NI, Uzoma G. Antioxidant Supplementation in 
Pregnancy: Effects on Maternal and Infant Health. Int. J. Adv. 
Multidiscip. Res. 2023;10(11):60-70. 

22. Obeagu EI, Obeagu GU. Mitigating Oxidative Stress in Pregnancy 
through Antioxidant Supplementation: A Narrative Review. Int. J. 
Curr. Res. Chem. Pharm. Sci. 2024;11(9):7-17. 

23. Obeagu EI, Obeagu GU. Enhancing Maternal and Fetal Well-being: 
The Role of Antioxidants in Pregnancy. Elite Journal of Medical 
Sciences. 2024;2(4):76-87. 

24. Obeagu EI, Obeagu GU. Antioxidant Supplementation and 
Prevention of Early Pregnancy Loss: A Narrative Review. Int. J. 
Curr. Res. Chem. Pharm. Sci. 2024;11(9):28-37. 
https://doi.org/10.22270/ijmspr.v10i4.120 

25. Obeagu EI, Obeagu GU. Molar Pregnancy: Update of prevalence and 
risk factors. Int. J. Curr. Res. Med. Sci. 2023;9(7):25-28. 
https://doi.org/10.19080/JGWH.2023.25.556169 

26. Obeagu EI, Obeagu GU. Hypoxia-induced Metabolic Changes in 
Pregnancy: Clinical Perspectives. Elite Journal of Medicine. 
2024;2(8):50-59. 

27. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women 
with Sickle Cell Anemia: A Review. Elite Journal of Haematology. 
2024;2(3):67-80. 

 

 

https://doi.org/10.1155/2014/576738
https://doi.org/10.1515/CCLM.2008.355
https://doi.org/10.22270/ijmspr.v10i4.121
https://doi.org/10.22270/ijmspr.v10i2.103
https://doi.org/10.22270/ijmspr.v10i4.120
https://doi.org/10.19080/JGWH.2023.25.556169

